|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Nant_Omics
gptkb:Nant_Pharma
|
|
gptkbp:awards
|
Best Biotech Company (2019)
Healthcare Innovation Award (2021)
Innovative Company Award (2020)
|
|
gptkbp:ceo
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:collaborations
|
gptkb:UCLA
gptkb:Johns_Hopkins_University
|
|
gptkbp:employees
|
100-200
|
|
gptkbp:focus
|
Cancer treatment
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:founder
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:goal
|
Improve patient outcomes
Reduce healthcare costs
Transform cancer treatment
|
|
gptkbp:headquarters
|
gptkb:Culver_City,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nant Cell, Inc.
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:investment
|
$100 million
|
|
gptkbp:key_people
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:notable_work
|
gptkb:Nant_Health
Nant Cancer Vaccine
Nant KID
|
|
gptkbp:partnership
|
Various research institutions
|
|
gptkbp:philosophy
|
Patient-centered care
Collaborative research
Innovative therapies
|
|
gptkbp:products
|
gptkb:Nant_Health
Nant Cancer Vaccine
Nant KID
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
gptkb:vaccine
Cell therapy
Gene therapy
Regenerative medicine
Clinical trials
Precision medicine
Pharmacogenomics
Biomarker discovery
Targeted therapy
Translational medicine
|
|
gptkbp:research_focus
|
Personalized medicine
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:subsidiary
|
gptkb:Nant_Works
|
|
gptkbp:technology
|
gptkb:Artificial_Intelligence
Data analytics
Genomic sequencing
|
|
gptkbp:type
|
gptkb:football_club
|
|
gptkbp:website
|
www.nantcell.com
|
|
gptkbp:bfsParent
|
gptkb:Nant_Kwest,_Inc.
|
|
gptkbp:bfsLayer
|
3
|